[
  {
    "ts": "2025-10-19T14:30:00+00:00",
    "headline": "Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy. The study used the new subcutaneous formulation of amivantamab, which can be delivered in a five-minute",
    "url": "https://finance.yahoo.com/news/subcutaneous-amivantamab-delivers-promising-45-143000700.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "39f7510d-0391-39ea-a762-8e5e3285ce0d",
      "content": {
        "id": "39f7510d-0391-39ea-a762-8e5e3285ce0d",
        "contentType": "STORY",
        "title": "Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy. The study used the new subcutaneous formulation of amivantamab, which can be delivered in a five-minute",
        "pubDate": "2025-10-19T14:30:00Z",
        "displayTime": "2025-10-19T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-amivantamab-delivers-promising-45-143000700.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-amivantamab-delivers-promising-45-143000700.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]